Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

KOL Insight: Oncology Solid Tumour Review (2018 Q2)

Product Code:
596201277
Publication Date:
July 2018
Format:
PDF + PPTX
Price:
$5,995

KOLs speak out on recent events in the solid tumour landscape

With so much happening in the solid tumour treatment landscape it’s important to understand how things are likely to evolve. Based on the insights of two dozen of the world’s foremost key opinion leaders (KOLs) from Europe and the US, KOL Insight: Oncology Solid Tumour Review (2018 Q2) cuts through the hype to provide much needed clarity on key events in eight different solid tumours, including bladder cancer, colorectal cancer (CRC), glioblastoma, head and neck cancer, melanoma, non-small cell lung cancer (NSCLC), prostate cancer and renal cell carcinoma. What do KOLs think about data for Keytruda, Tecentriq and Opdivo in NSCLC? How do KOLs see the management of prostate cancer changing in the next few years, following the US approval of J&J’s Erleada (apalutamide), and new data for Xtandi (Pfizer/Astellas). Where in the future treatment paradigm for certain tumours could novel approaches be used, including precision cancer vaccines in mCRC, endosomal TLR9 agonists in melanoma and PI3K/AKT/mTOR pathway inhibitors in glioblastoma? Learn about these developments, along with many more in KOL Insight: Oncology Solid Tumour Review (2018 Q2).

Top takeaways

  • Keytruda in NSCLC and melanoma. What do KOLs think about data from the KEYNOTE-189 trial of Keytruda in combination with chemotherapy, for the first-line treatment of patients with advanced NSCLC, and how the failure of the Phase III KEYNOTE-252 trial in patients with melanoma could shape epacadostat’s (Incyte) future.
  • New dosing schedule for Opdivo, plus Opdivo/Yervoy data in NSCLC. The potential impact of the FDA approving a once every four weeks dosing schedule for Opdivo (BMS), and what KOLs think about the data from the Phase III CheckMate-227 trial, which is evaluating the Opdivo/Yervoy combination in first-line treatment of advanced NSCLC.
  • Clinical trial data for Tecentriq in mCRC, RCC and NSCLC. What the future holds for Tecentriq(Roche) in the treatment of mCRC, RCC and NSCLC, following the announcement of the results of the Phase III IMBlaze370, IMmotion151 and IMpower131 studies. 
  • What next for Bavencio (avelumab) in RCC? How can Merck Group/Pfizer leverage recent clinical data readouts from the Phase III REACH study (head and neck cancer) and the Phase Ib JAVELIN RENAL 100 study (renal cell carcinoma) for Bavencio.
  • New approvals and clinical data in prostate cancer. How do KOLs see the management of prostate cancer changing in the next few years, following the US approval of J&J’s Erleada (apalutamide), and data being announced from the Phase III PROSPER study for well-established agent Xtandi (Pfizer/Astellas).
  • The future of novel therapies in mCRC, glioblastoma and melanoma. Where in the future treatment paradigm for certain tumours could novel approaches be used, including precision cancer vaccines in mCRC, endosomal TLR9 agonists in melanoma and PI3K/AKT/mTOR pathway inhibitors in glioblastoma.
Request sample pages

Back to the top

Quotes

“We’re really [embedded] with Tecentriq and Keytruda. Opdivo’s new dosing schedule will impact these a little bit, but not that much. I expect that in a year, Keytruda and Tecentriq will still have the lion’s share of the market.”
US Key Opinion Leader

“I was very disappointed [with ECHO-301] because there were several caveats in the previous [Phase I/II] study. There was a 57 percent response rate with pembrolizumab plus epacadostat; because pembrolizumab alone could go over 50 percent if you select the patients properly, that leads to a substantially higher response rate than with PDL1-negative patients.”
EU Key Opinion Leader

Sample of therapies covered

Marketed Therapies

  • Bavencio (avelumab; Merck Group/Pfizer)
  • Erleada (apalutamide; Johnson & Johnson)
  • Fotivda (tivozanib; AVEO Oncology/EUSA Pharma)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Lenvima (lenvatinib; Eisai)
  • Opdivo (nivolumab; Bristol-Myers Squibb)
  • Tecentriq (atezolizumab; Roche)
  • Xtandi (enzalutamide; Pfizer/Astellas)
  • Zytiga (abiraterone acetate; Johnson & Johnson)

Pipeline Therapies

  • Dianhydrogalactitol (VAL-083; DelMar Pharmaceuticals)
  • Enfortumab vedotin (ASG-22ME; Astellas/Seattle Genetics)
  • Epacadostat (Incyte Pharmaceuticals)
  • GDC-0084 (Kazia Therapeutics)
  • Indoximod (NewLink Genetics)
  • Monalizumab (Innate Pharma)
  • Rogaratinib (BAY1163877; Bayer)
  • PolyPEPI 1018 (precision cancer vaccine; Treos Bio)
  • SD-101 (Dynavax Technologies)
  • Talazoparib (Pfizer)
  • Tanibirumab (TTAC-0001; PharmAbcine)
  • Tilsotolimod (IMO-2125; Idera Pharmaceuticals)

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved